CHANNELS

Subscribe to the InfoTech eNewsletter

infoTECH News

TMCNet:  Research and Markets: Influvac (Seasonal Influenza Vaccine) Forecast and Market Analysis 2012-2022

[January 11, 2013]

Research and Markets: Influvac (Seasonal Influenza Vaccine) Forecast and Market Analysis 2012-2022

DUBLIN --(Business Wire)--

Research and Markets (http://www.researchandmarkets.com/research/rfgzg5/influvac) has announced the addition of GlobalData's new report "Influvac (Seasonal Influenza Vaccine) Forecast and Market Analysis" to their offering.

Influvac (Seasonal Influenza Vaccine) Forecast and Market Analysis. Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. The market is heavily driven by the sales of prophylactic vaccine treatments to prevent infection. Currently, trivalent intramuscular vaccines such as Sanofi's Fluzone and Vaxigrip, GlaxoSmithKline's Fluarix and FluLaval and Novartis' Fluvirin garner the majority stake of the market. However, with the entrance of vaccines with novel routes of administration, such as AstraZeneca's intranasal FluMist and Sanofi's Fluzone IntraDeral, GlobalData projects a dramatic shift favoring the adoption of such vaccines over the traditional intramuscular vaccines. GlobalData also anticipates that manufacturers that launch quadrivalent formulations will steal market share, patient share, and revenue from the trivalent influenza vaccines currently available.

Influvac is a trivalent, inactivated sub-unit vaccine designed to immunize recipients against seasonal influenza infection. The viral subtypes used in Influvac are propagated in chicken eggs, inactivated, and purified by centrifugation. Influvac is marketed by Abbott, as part of its acquisition of Solvay Pharmaceuticals in 2010. Influvac is expected to lose market share throughout Europe, as we expect quadrivalent influenza vaccines to dominate the European market by 2022.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return

- Stay ahead of the competition by understanding the changing competitive landscape for seasonal influenza

- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential

- Make more informed business decisions from insightful and in-depth analysis of Influvac performance

- Obtain sales forecast for Influvac from 2012 to 2022 in France, Germany, Italy, Spain and China.

Key Topics Covered:

1 Tables & Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Appendix

For more information visit http://www.researchandmarkets.com/research/rfgzg5/influvac

Source (News - Alert): GlobalData


[ InfoTech Spotlight's Homepage ]


blog comments powered by Disqus

FOLLOW US

Subscribe to InfoTECH Spotlight eNews

InfoTECH Spotlight eNews delivers the latest news impacting technology in the IT industry each week. Sign up to receive FREE breaking news today!
FREE eNewsletter